Buy Torrent Pharmaceuticals; target of Rs 5581: Geojit Financial Services
Geojit Financial Services research report on Torrent Pharmaceuticals
Torrent Pharmaceuticals Ltd is engaged in the research, development, manufacturing and marketing of generic pharmaceutical formulations. It has operations in India, the US, Germany and Brazil. Torrent’s products cover a wide range of therapeutic areas. Consolidated revenue rose 50.8% YoY to Rs. 4,979cr, driven by the inclusion of JB Pharma and robust growth of 18% in the base business, led by strong performance of branded formulations. India revenue rose 57.0% YoY to Rs. 2,861cr, driven by strong performance in the chronic portfolio, growth at Curatio, field-force expansion and traction in Semaglutide. International revenue rose 48.0% YoY to Rs. 1,991cr, supported by i) strong growth in Brazil from top brands and new launches and ii) growth in the US from new launches. EBITDA rose 53.8% YoY to Rs. 1,666cr, with margin improving 70bps to 33.5%, aided by synergy realisation, field-force optimisation and procurement benefits. PAT fell 9.9% YoY to Rs. 544cr, primarily impacted by higher finance costs following the JB Pharma acquisition and acquisition-related increase in borrowings.
Outlook
Strength in Brazil and the US, along with ongoing synergy benefits, is expected to support growth visibility and reinforce long-term earnings prospects. Therefore, we upgrade our rating to BUY on the stock with a target price of Rs. 5,581, based on 29x FY28E EV/EBITDA. Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. Torrent Pharmaceuticals - 0511026 - geo